The European Medicines Agency's human medicines committee based its endorsement on Phase 3 clinical trial results, which highlighted the medication's performance in treatment-naive patients. Researchers noted that the data demonstrates both strong tolerability and a meaningful clinical impact for those diagnosed with the condition. The European Commission is now expected to finalize marketing authorization within the next two months.

Simultaneously, Eli Lilly is working to expand the drug's reach beyond Europe. The company has submitted its trial findings to the U.S. Food and Drug Administration, with a regulatory decision anticipated during the second half of this year.